SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response

Abstract excerpt

Poor clinical outcomes in cancer can often be attributed to inadequate response to chemotherapy. Strategies to overcome either primary or acquired chemoresistance may ultimately impact on patients' survival favourably. We previously showed that lower levels of SPARC were associated with therapy-refractory colorectal cancers (CRC), and that upregulating its expression enhances chemo-sensitivity resulting in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bone and Dental Protein Studies
• Share to Epigenetics and DNA Methylation
• Share to Pancreatic and Hepatic Oncology Research